Zimmer Story

All StoriesForecast
Raphi Shpitalnik Story
<div class='circular--portrait' style='background:#FF6600;color: #FFF8DC;font-size:4em;'>ZB</div>
ZBH -- USA Stock  

USD 161.19  4.94  3.16%

Macroaxis News
By Raphi Shpitalnik  
Macroaxis Story
Zimmer Biomet Average Assets are most likely to increase significantly in the upcoming years. The last year's value of Average Assets was reported at 22.1 Billion. The current Earnings before Tax is estimated to increase to about 142.2 M, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are projected to decrease to roughly 1.6 B. The primary intention for this outlook is to break down Zimmer potential for March. We are going to examine if Zimmer Biomet is reasonably priced going into March.
Published over three weeks ago
View all stories for Zimmer Biomet | View All Stories
Here is our Zimmer Biomet (NYSE:ZBH) forecasting for March
Over 91.0% of Zimmer Biomet outstanding shares are owned by institutional investors. Institutional ownership of Zimmer Biomet Holdings refers to the amount of Zimmer Biomet Holdings equity owned by mutual funds, pension funds, insurance companies, investment firms, foundations, or other large entities that manage money on behalf of others. Check out our latest analysis of Zimmer, including its current ownership diagnostics.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Zimmer Biomet Holdings. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Zimmer Biomet

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Zimmer Biomet's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Zimmer Biomet in the context of predictive analytics.
Hype
Prediction
Details
Intrinsic
Valuation
Details
Naive
Forecast
Details
22 Analysts
Consensus
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Zimmer Biomet. Your research has to be compared to or analyzed against Zimmer Biomet's peers to derive any actionable benefits. When done correctly, Zimmer Biomet's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Zimmer Biomet Holdings.

How important is Zimmer Biomet's Liquidity

Zimmer Biomet financial leverage refers to using borrowed capital as a funding source to finance Zimmer Biomet Holdings ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Zimmer Biomet financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Zimmer Biomet's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Zimmer Biomet, but it might be worth checking our own buy vs. sell analysis

Exercise or conversion by Ivan Tornos of 517 shares of Zimmer Biomet subject to Rule 16b-3

Legal trades by Zimmer Biomet insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Zimmer insider trading alert for exercise of restricted stock units by Ivan Tornos, Grp Pres Global Bus & Americas, on 2nd of March 2021. This event was filed by Zimmer Biomet Holdings In with SEC on 2021-03-02. Statement of changes in beneficial ownership - SEC Form 4. Ivan Tornos currently serves as group president - global businesses and americas of Zimmer Biomet Holdings [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down Zimmer Biomet Further

Zimmer Biomet Holdings has relatively low volatility with skewness of 2.59 and kurtosis of 13.53. However, we advise all investors to independently investigate Zimmer Biomet Holdings to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns.

Returns Breakdown

5.88
Return on Assets
8.28
Return on Investment
Return on Investment8.28
Return on Assets5.88
Return on Equity10.95
Return Capital0.0319
Return on Sales0.0862

Will Zimmer continue to rise?

Current Information Ratio is up to 0.03. Price may drop again. Zimmer Biomet Holdings has relatively low volatility with skewness of 2.59 and kurtosis of 13.53. However, we advise all investors to independently investigate Zimmer Biomet Holdings to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns.

Our Takeaway on Zimmer Biomet Investment

While some other firms under the medical devices industry are still a bit expensive, Zimmer Biomet may offer a potential longer-term growth to stockholders. To summarize, as of the 5th of February 2021, our research shows that Zimmer Biomet is a rather very steady investment opportunity with a below average chance of bankruptcy in the next two years. From a slightly different view, the entity currently appears to be fairly valued. Our primary 30 days 'Buy-vs-Sell' recommendation on the company is Strong Buy.

About Contributor

Raphi Shpitalnik is a Junior Member of Macroaxs Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time base at the beginning of the pandemic and eventually acquired a real test for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Zimmer Biomet Holdings. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
Macroaxis Wealth Optimization Platform
 
Feedback Blog
Made with optimal in San Francisco
2021 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY